Your selection
Research / 27.03.2026
Friedrich Stolz Award for the Tubulis Team
The Medicinal Chemistry Division of the Gesellschaft Deutscher Chemiker (GDCh) and the Pharmaceutical/Medicinal Chemistry Division of the Deutsche Pharmazeutische Gesellschaft (DPhG) have awarded the Friedrich Stolz Award 2026 to the team from Tubulis, a spin-off of the Leibniz-Forschungsinstitut für Molekulare Pharmakologie and LMU Munich. Honored are Prof. Dr. Christian Hackenberger from the Leibniz-FMP as co-founder and advisor and Dr. Jonas Helma-Smets, co-founder and CSO, Dr. Marc-André Kasper, VP Chemistry and Early Discovery and Dr. Annette Vogl, VP Biology and Translational Research, from Tubulis.
The Friedrich Stolz Award recognizes exceptional dedication, scientific discoveries, or innovative technologies with proven relevance that contribute to substantial therapeutic innovation or sustainable development and go beyond early research stages.
The Tubulis team was awarded for their P5 ethynylphosphonamidate conjugation chemistry, enabling a novel type of antibody-drug conjugates (ADCs).The conjugation chemistry, also termed P5-labeling, was developed at FMP in the research unit of Christian Hackenberger. This new ADC class is characterized by exceptional plasma stability, favorable pharmacokinetic properties, and pronounced anti-tumor efficacy. Building on this, NaPi2b-targeting exatecan ADCs with particularly stable linkers, reduced off-target toxicity, and optimized molecular architecture were generated. The culmination of this work is the development candidate TUB-040, which in a clinical Phase 1 study in patients with platinum-resistant ovarian cancer demonstrates promising tumor remissions, a wide therapeutic window, and good tolerability. This work shows how innovative chemistry can be directly translated into novel, potentially more effective treatment options for hard-to-treat cancers.
The prize is awarded in memory of industrial pharmacist and drug researcher Friedrich Stolz, whose visionary innovative power serves as a model for application-oriented, therapeutically relevant research.
Photo: Awarded the Friedrich Stolz Prize: Prof. Dr. Stefan Laufer (GDCh), Prof. Dr. Christian Hackenberger, Dr. Annette Vogl, Dr. Jonas Helma-Smets and Dr. Franz von Nussbaum (from left to right). © GDCh
Source: FMP
Friedrich Stolz Award for the Tubulis Team
Overview News
News Buch Berlin
Eckert & Ziegler with a Successful Start to the Year. 2026 Forecast Confirmed.
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased its sales in the first quarter of 2026 by 7% to €72.9 million compared with the same period last year.
more ...First Joint Career Day Brings Science and Industry Together
The Max Delbrück Center’s Career Day, held in cooperation with the operator of the Berlin-Buch Campus, offered young researchers insights into the working world of startups and biotech companies
more ...A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect
A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers have succeeded in developing a so-called nanobody that penetrates directly int...
more ...Events Buch Berlin
19.05.2026, 18:00
Campus-Kino: "Human Flow"
Der Künstler und Aktivist Ai Weiwei zeigt die Folgen der Flüchtlingskrise. Dazu reiste er mit Kameramännern in 23 Länder, sprach mit den Menschen und lernte ihre Schicksale kennen. Die filmische Reise...
more ...20.05.2026, 13:00
Herzliche Einladung zur CampusVital LOUNGE: "Wie das Geschlecht unsere Gesundheit prägt"
Ein Ausflug in die Welt des Stoffwechsels und geschlechtsspezifischer Unterschiede vorgestellt von Raphaela Fritsche.
more ...21.05.2026, 17:00
Open-Air-Sprechstunde der Bezirksbürgermeisterin Cordelia Koch am 21. Mai
Im Garten des StadtTeilZentrum des Frei-Zeit-Haus e.V. - Anmeldung erbeten
more ...
